PT3110837T - Proteínas de fusão tatk-cdkl5, composições, formulações e seu uso - Google Patents

Proteínas de fusão tatk-cdkl5, composições, formulações e seu uso

Info

Publication number
PT3110837T
PT3110837T PT15736034T PT15736034T PT3110837T PT 3110837 T PT3110837 T PT 3110837T PT 15736034 T PT15736034 T PT 15736034T PT 15736034 T PT15736034 T PT 15736034T PT 3110837 T PT3110837 T PT 3110837T
Authority
PT
Portugal
Prior art keywords
tatk
formulations
compositions
fusion proteins
cdkl5 fusion
Prior art date
Application number
PT15736034T
Other languages
English (en)
Inventor
Ciani Elisabetta
Laccone Franco
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of PT3110837T publication Critical patent/PT3110837T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
PT15736034T 2014-02-28 2015-02-27 Proteínas de fusão tatk-cdkl5, composições, formulações e seu uso PT3110837T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
PT3110837T true PT3110837T (pt) 2019-09-12

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191792878T PT3608334T (pt) 2014-02-28 2015-02-27 Proteínas de fusão tatk-cdkl5, composições, formulações e utilização das mesmas
PT15736034T PT3110837T (pt) 2014-02-28 2015-02-27 Proteínas de fusão tatk-cdkl5, composições, formulações e seu uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT191792878T PT3608334T (pt) 2014-02-28 2015-02-27 Proteínas de fusão tatk-cdkl5, composições, formulações e utilização das mesmas

Country Status (33)

Country Link
US (4) US9290746B2 (pt)
EP (2) EP3110837B1 (pt)
JP (2) JP6629747B2 (pt)
KR (1) KR102307276B1 (pt)
CN (1) CN106255706A (pt)
AU (2) AU2015221860B2 (pt)
BR (1) BR112016019868B1 (pt)
CA (1) CA2940401C (pt)
CL (1) CL2016002142A1 (pt)
CR (1) CR20160392A (pt)
CY (2) CY1122644T1 (pt)
DK (2) DK3608334T3 (pt)
DO (1) DOP2016000220A (pt)
EA (2) EA202190727A3 (pt)
ES (2) ES2745335T3 (pt)
HR (2) HRP20191511T1 (pt)
HU (2) HUE055282T2 (pt)
IL (2) IL247481B (pt)
LT (2) LT3608334T (pt)
MX (2) MX392778B (pt)
MY (1) MY181566A (pt)
NI (1) NI201600127A (pt)
PE (1) PE20161406A1 (pt)
PH (1) PH12016501689B1 (pt)
PL (2) PL3608334T3 (pt)
PT (2) PT3608334T (pt)
RS (2) RS62244B1 (pt)
SG (2) SG10202000537RA (pt)
SI (2) SI3110837T1 (pt)
SM (2) SMT202100478T1 (pt)
SV (1) SV2016005264A (pt)
WO (1) WO2015128746A2 (pt)
ZA (2) ZA201606655B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3110837T1 (sl) * 2014-02-28 2019-12-31 Alma Mater Studiorum - Universita Di Bologna Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba
BR112018077225A2 (pt) * 2016-06-28 2019-04-09 Alma Mater Studiorum - Università di Bologna proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
KR20200090889A (ko) * 2017-11-30 2020-07-29 아미쿠스 세라퓨틱스, 인코포레이티드 Cdkl5 발현 변이체 및 cdkl5 융합 단백질
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
CA3156506A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
JP2024531296A (ja) * 2021-08-18 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えaav製剤
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815582A1 (en) * 2010-10-25 2012-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Treatment of mecp2-associated disorders
SI3110837T1 (sl) * 2014-02-28 2019-12-31 Alma Mater Studiorum - Universita Di Bologna Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba

Also Published As

Publication number Publication date
DK3608334T3 (da) 2021-08-23
IL275435A (en) 2020-08-31
EP3608334B1 (en) 2021-05-19
US20160194617A1 (en) 2016-07-07
WO2015128746A3 (en) 2015-11-26
MX2020001223A (es) 2022-05-31
NI201600127A (es) 2017-03-13
AU2019219743B2 (en) 2020-10-29
EA202190727A3 (ru) 2021-11-30
CA2940401C (en) 2022-11-29
JP2020062022A (ja) 2020-04-23
ES2885245T3 (es) 2021-12-13
EA038000B1 (ru) 2021-06-22
SV2016005264A (es) 2017-02-15
EP3608334A1 (en) 2020-02-12
ZA201906304B (en) 2022-03-30
BR112016019868B1 (pt) 2023-11-28
PL3608334T3 (pl) 2021-11-22
MX2016011167A (es) 2017-04-06
US20150247134A1 (en) 2015-09-03
EA201691691A1 (ru) 2017-05-31
PH12016501689A1 (en) 2016-10-03
SG10202000537RA (en) 2020-03-30
SMT201900504T1 (it) 2019-11-13
RS62244B1 (sr) 2021-09-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20200199549A1 (en) 2020-06-25
HRP20211324T1 (hr) 2021-11-26
MX392778B (es) 2025-03-24
AU2019219743A1 (en) 2019-09-19
HRP20191511T1 (hr) 2019-11-29
US9290746B2 (en) 2016-03-22
CA2940401A1 (en) 2015-09-03
US9944910B2 (en) 2018-04-17
AU2015221860B2 (en) 2019-09-12
PL3110837T3 (pl) 2020-04-30
PT3608334T (pt) 2021-08-25
WO2015128746A2 (en) 2015-09-03
BR112016019868A2 (pt) 2017-10-17
KR102307276B1 (ko) 2021-09-30
US10907138B2 (en) 2021-02-02
EA202190727A2 (ru) 2021-07-30
US10584318B2 (en) 2020-03-10
SI3110837T1 (sl) 2019-12-31
AU2015221860A1 (en) 2016-09-08
CL2016002142A1 (es) 2017-09-08
HUE045393T2 (hu) 2019-12-30
ZA201606655B (en) 2020-05-27
JP2017507655A (ja) 2017-03-23
JP6629747B2 (ja) 2020-01-15
NZ723371A (en) 2023-11-24
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
SMT202100478T1 (it) 2021-09-14
DK3110837T3 (da) 2019-09-16
PE20161406A1 (es) 2017-01-14
IL247481B (en) 2020-07-30
CY1124727T1 (el) 2022-07-22
US20180327725A1 (en) 2018-11-15
KR20170002372A (ko) 2017-01-06
CR20160392A (es) 2017-06-12
SG11201606863YA (en) 2016-09-29
CN106255706A (zh) 2016-12-21
IL247481A0 (en) 2016-11-30
JP6896050B2 (ja) 2021-06-30
EP3110837B1 (en) 2019-06-12
ES2745335T3 (es) 2020-02-28
HUE055282T2 (hu) 2021-11-29
RS59344B1 (sr) 2019-10-31
PH12016501689B1 (en) 2016-10-03
SI3608334T1 (sl) 2021-11-30
LT3110837T (lt) 2019-10-10
DOP2016000220A (es) 2016-12-15
EP3110837A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
IL257030A (en) Multivalent and multispecific cleavage proteins that bind to gitr Preparations containing them and uses thereof
ZA201707749B (en) Compounds targeting proteins, compositions, methods, and uses thereof
IL275435B (en) tatk-cdkl5 fusion proteins, preparations, formulations, and their uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
EP3191114A4 (en) Occidiofungin formulations and uses thereof
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
LT3223796T (lt) Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
PL3229843T3 (pl) Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
HK1234652A1 (en) Protein formulations